The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 32, Issue , 2015, Pages 53-59

  Beeh, Kai Michael ^a   Westerman, Jan ^b   Kirsten, Anne Marie ^c   Hébert, Jacques ^d   Grönke, Lars ^e   Hamilton, Alan ^f   Tetzlaff, Kay ^e,g   Derom, Eric ^h  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b Pulmonary and Sleep Associates of Jasper   (United States)

^c Lung Clinic Grosshansdorf   (Germany)

^d Centre de Recherche Appliquée en Allergie de Québec   (Canada)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Combination therapy; Olodaterol; Tiotropium

Indexed keywords

OLODATEROL; PLACEBO; TIOTROPIUM BROMIDE; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INCIDENCE; INSPIRATORY CAPACITY; LUNG FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOFT MIST INHALER; TOTAL LUNG CAPACITY; VASCULAR DISEASE; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; LUNG FUNCTION TEST; MULTICENTER STUDY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84930518106     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.04.002     Document Type: Article

References (24)

1. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A4-year trial of tiotropium in chronic obstructive pulmonary disease. N.Engl. J. Med. 2008, 359:1543-1554. 10.1056/NEJMoa0805800.
2. ® plus usual therapy in COPD patients. Respir. Med. 2010, 104:1460-1472.
3. Cooper C.B., Celli B.R., Jardim J.R., Wise R.A., Legg D., Guo J., et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013, 144:490-497.
4. Yohannes A.M., Willgoss T.G., Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir. Care 2011, 56:477-487.
5. Vogelmeier C., Hederer B., Glaab T., Schmidt H., Rutten-van Mölken M.P.M.H., Beeh K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N.Engl. J. Med. 2011, 364:1093-1103. 10.1056/NEJMoa1008378.
6. Wise R.A., Anzueto A., Cotton D., Dahl R., Devins T., Disse B., et al. Tiotropium Respimat inhaler and the risk of death in COPD. N.Engl. J. Med. 2013, 369:1491-1501.
7. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J.Pharmacol. Exp. Ther. 2010, 334:53-62.
8. Casarosa P., Kollak I., Kiechle T., Ostermann A., Schnapp A., Kiesling R., et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J.Pharmacol. Exp. Ther. 2011, 337:600-609.
9. ® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies. Springerplus 2014, 3:419.
10. ® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9:629-645. 10.2147/COPD.S61717.
11. ® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9:697-714. 10.2147/COPD.S62502.
12. Lange P., Aumann J.-L., Hamilton A., Tetzlaff K., Ting N., Derom E. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J.Pulm. Respir. Med. 2014, 4:196. 10.4172/2161-105X.1000196.
13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. (accessed 02.06.14). http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf.
14. Bouyssou T., Schnapp A., Casarosa P., Pieper M.P. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models. Am. J. Respir. Crit. Care Med. 2010, 181. abs A4445.
15. ® inhaler in patients with COPD. Eur. Respir. J. 2012, 40(Suppl.56):525s-526s. abs P2882.
16. Maltais F., Beck E., Webster D., Maleki-Yazdi M.R., Seibt J.-V., Arnoux A., et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur. Respir. J. 2010, 36(Suppl 54). 1014s, abs 5557.
17. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008, 31:416-469. 10.1183/09031936.00099306.
18. Beeh K.-M., Korn S., Beier J., Jadayel D., Henley M., D'Andrea P., et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014, 108:584-592. 10.1016/j.rmed.2014.01.006.
19. Wanger J., Clausen J.L., Coates A., Pedersen O.F., Brusasco V., Burgos F., et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. 2005, 26:511-522. 10.1183/09031936.05.00035005.
20. Bateman E.D., Mahler D.A., Vogelmeier C.F., Wedzicha J.A., Patalano F., Banerji D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev. Respir. Med. 2014, 8:357-379.
21. Jones P.W., Beeh K.M., Chapman K.R., Decramer M., Mahler D.A., Wedzicha J.A. Minimal clinically important differences in pharmacological trials. Am. J. Respir. Crit. Care Med. 2014, 189:250-255.
22. Buhl R., Maltais F., Abrahams R., Bjermer L., Derom E., Ferguson G., et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur. Respir. J. 2015, 45:969-979.
23. Tashkin D.P., Ferguson G.T. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res. 2013, 14:49.
24. Calverley P.M.A., Lee A., Towse L., van Noord J., Witek T.J., Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003, 58:855-860.